Terms: = Kidney tumors AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
26 results:
1. Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus.
Nakayama Y; Enomoto D; Yamamoto K; Takara K
Anticancer Res; 2023 Oct; 43(10):4349-4357. PubMed ID: 37772579
[TBL] [Abstract] [Full Text] [Related]
2. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract] [Full Text] [Related]
3. Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
Grahn A; Eisfeldt J; Malm C; Foroughi Asl H; Jaremko G; Tham E; Brehmer M
BJU Int; 2022 Jul; 130(1):92-101. PubMed ID: 34375486
[TBL] [Abstract] [Full Text] [Related]
4. Concomitant Acute Tubular Necrosis and Acute Interstitial Nephritis Induced by Tipifarnib in a Patient with Squamous Cell Carcinoma of the Lung.
Martinez de la Cruz P; Shabaka A; Mielgo-Rubio X; Guerrero-Marquez C; Gimenez-Moyano S; Fernandez-Juarez G
Am J Med Sci; 2021 Jul; 362(1):99-102. PubMed ID: 33872582
[TBL] [Abstract] [Full Text] [Related]
5. The effect of microRNA-330 replacement on inhibition of growth and migration in renal cancer cells.
Liu J; Song X; Ren Z
Biotechnol Appl Biochem; 2022 Apr; 69(2):558-566. PubMed ID: 33605482
[TBL] [Abstract] [Full Text] [Related]
6. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.
Sfakianos JP; Gul Z; Shariat SF; Matin SF; Daneshmand S; Plimack E; Lerner S; Roupret M; Pal S
Eur Urol Oncol; 2021 Apr; 4(2):170-179. PubMed ID: 33386276
[TBL] [Abstract] [Full Text] [Related]
7. Cell autonomous angiotensin II signaling controls the pleiotropic functions of oncogenic k-ras.
Volonte D; Sedorovitz M; Cespedes VE; Beecher ML; Galbiati F
J Biol Chem; 2021; 296():100242. PubMed ID: 33380422
[TBL] [Abstract] [Full Text] [Related]
8. Formylated honokiol analogs showed antitumor activity against lung carcinoma.
Deng S; Zhang C; Yang L; Ma L
Anticancer Drugs; 2019 Sep; 30(8):795-802. PubMed ID: 30807551
[TBL] [Abstract] [Full Text] [Related]
9. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.
Zhai W; Sun Y; Guo C; Hu G; Wang M; Zheng J; Lin W; Huang Q; Li G; Zheng J; Chang C
Cell Death Differ; 2017 Sep; 24(9):1502-1517. PubMed ID: 28644440
[TBL] [Abstract] [Full Text] [Related]
10. Potentiating effects of GHRH analogs on the response to chemotherapy.
Schally AV; Perez R; Block NL; Rick FG
Cell Cycle; 2015; 14(5):699-704. PubMed ID: 25648497
[TBL] [Abstract] [Full Text] [Related]
11. Evidence for aldosterone-dependent growth of renal cell carcinoma.
King S; Bray S; Galbraith S; Christie L; Fleming S
Int J Exp Pathol; 2014 Aug; 95(4):244-50. PubMed ID: 24802662
[TBL] [Abstract] [Full Text] [Related]
12. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Lin F; de Gooijer MC; Roig EM; Buil LC; Christner SM; Beumer JH; Würdinger T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2014 May; 20(10):2703-13. PubMed ID: 24647572
[TBL] [Abstract] [Full Text] [Related]
13. Administration of chemotherapy by an arteriovenous fistula in a patient with metastatic rectal cancer after life-threatening, port thrombosis-associated cava superior syndrome. An option for patients without possibility of peripheral or central venous access.
Stein A; Hiemer S; Jordan K; Arnold D; Schmoll HJ
Onkologie; 2012; 35(7-8):440-2. PubMed ID: 22846976
[TBL] [Abstract] [Full Text] [Related]
14. Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition.
Guo W; Wu S; Wang L; Wei X; Liu X; Wang J; Lu Z; Hollingshead M; Fang B
PLoS One; 2011; 6(12):e28487. PubMed ID: 22174819
[TBL] [Abstract] [Full Text] [Related]
15. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.
Basu A; Banerjee P; Contreras AG; Flynn E; Pal S
PLoS One; 2011; 6(8):e23919. PubMed ID: 21886838
[TBL] [Abstract] [Full Text] [Related]
16. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal.
Banerjee P; Basu A; Datta D; Gasser M; Waaga-Gasser AM; Pal S
J Biol Chem; 2011 Sep; 286(38):33580-90. PubMed ID: 21808062
[TBL] [Abstract] [Full Text] [Related]
17. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine.
Lund P; Kotova I; Kedinger V; Khanwalkar H; Voltz E; Hahn WC; Gronemeyer H
Mol Cancer Ther; 2011 Sep; 10(9):1611-23. PubMed ID: 21697397
[TBL] [Abstract] [Full Text] [Related]
18. Antitumor activity of novel indirubin derivatives in rat tumor model.
Kim SA; Kim YC; Kim SW; Lee SH; Min JJ; Ahn SG; Yoon JH
Clin Cancer Res; 2007 Jan; 13(1):253-9. PubMed ID: 17200363
[TBL] [Abstract] [Full Text] [Related]
19. Tyrosine phosphorylation of the Rab24 GTPase in cultured mammalian cells.
Ding J; Soule G; Overmeyer JH; Maltese WA
Biochem Biophys Res Commun; 2003 Dec; 312(3):670-5. PubMed ID: 14680817
[TBL] [Abstract] [Full Text] [Related]
20. Frequent RASSF1A promoter hypermethylation and k-ras mutations in pancreatic carcinoma.
Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
[TBL] [Abstract] [Full Text] [Related]
[Next]
